



2006 3rd quarter: sales up 9%

€ millions	2006	2005	% change
Q3 Sales	24.89	22.76	9%
France, including overseas dependencies	11.96	10.83	10%
Subsidiaries (1)	9.73	8.88	10%
Distributors	3.20	3.05	5%
Cumulative sales at end September	89.09	78.89	13%
France, including overseas dependencies	47.18	41.61	13%
Subsidiaries (1)	31.96	28.44	12%
Distributors	9.95	8.84	13%

(1) Germany, Belgium, Italy, Spain and Portugal.

3rd quarter growth was in keeping with 2nd quarter growth.

- In France, the increase in sales remained satisfactory (up 10%) and new patients continued to be attracted.
- Even though subsidiary growth remained at a good level (up 10%), it was also more uneven: sales growth slowed down in Germany in a sluggish market, whereas Spain fully benefited from the successful integration of IPI.
- The traditionally more volatile distributor segment slowed down as expected (up 5%) following two quarters of strong growth.

Cumulative growth at end September was 13% (of which 12% was organic). As forecast, full year growth should exceed 10% for the sixth year running.

About STALLERGENES

Stallergènes Group is today the world's leading pharmaceutical laboratory specialising in allergen immunotherapy, both in terms of number of patients treated (N°1) and sales (N°2). In its 40 years of existence, Stallergènes has established itself as a dynamic player, frequently as an innovator, in the battle to prevent and cure allergies, rhinitis and asthma in particular. Stallergènes devotes over 15% of its sales to its Research and Development activities.

Stallergènes' development is focused on the French market and on international markets through its subsidiaries based in Germany, Spain, Italy, Portugal and Belgium, and its distributors based in Eastern Europe, North Africa and elsewhere.

Shares of the Group's parent company, Stallergènes SA, are listed on the Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN Code: FR0000065674

Reuters Code: GEN.PA

Bloomberg Code: GEN.FP



STALLERGENES

Albert SAPORTA – Chairman and CEO

Christian THIRY – Chief Financial Officer

Tél : +33 (0)1 55 59 20 95

PAVIE FINANCE

Lucile de FRAGUIER
Investor & Analyst Relations

Tel: + 33 (0)1 42 15 04 39

contact@pavie-finance.com